Hanan Amadid
Overview
Explore the profile of Hanan Amadid including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
114
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rudofsky G, Amadid H, Braae U, Catrina S, Kick A, Mandavya K, et al.
Diabetes Ther
. 2024 Nov;
16(1):73-87.
PMID: 39535683
Introduction: Oral semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1RA) approved for improving glycemic control in adults with type 2 diabetes (T2D). The PIONEER REAL program evaluates clinical and...
2.
Lassen M, Johansen N, Modin D, Catarig A, Vistisen B, Amadid H, et al.
Diabetes Obes Metab
. 2024 Aug;
26(11):5239-5250.
PMID: 39215626
Aims: To assess the level of adherence to glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment using real-world data and to investigate the sociodemographic and clinical factors associated with discontinuation of GLP-1RAs....
3.
Yabe D, Hamamoto Y, Kawanami D, Nishimura R, Terauchi Y, Amadid H, et al.
J Diabetes Investig
. 2024 Aug;
15(11):1566-1577.
PMID: 39172634
Aims/introduction: PIONEER REAL Japan was a non-interventional prospective study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice. Materials And Methods: Adults naïve to injectable glucose-lowering...
4.
Catrina S, Amadid H, Braae U, Dereke J, Ekberg N, Klanger B, et al.
Diabetes Ther
. 2024 Jul;
15(9):2079-2095.
PMID: 39052163
Introduction: The study was designed to assess outcomes with once-daily oral semaglutide in adults with type 2 diabetes (T2D) naïve to injectable glucose-lowering agents, in Swedish clinical practice. Methods: In...
5.
van Houtum W, Schrombges P, Amadid H, van Bon A, Braae U, Hoogstraten C, et al.
Diabetes Ther
. 2024 Jun;
15(8):1749-1768.
PMID: 38861137
Introduction: In this phase 4, multicentre, prospective, non-interventional PIONEER REAL Netherlands study, we assessed clinical outcomes associated with once-daily oral semaglutide use in real-world clinical practice in adults living with...
6.
Suzuki R, Amadid H, Major-Pedersen A, Yabe D
J Diabetes Investig
. 2024 May;
15(8):1047-1056.
PMID: 38711208
Aims/introduction: PIONEER REAL Japan was a non-interventional, multicenter, prospective study investigating oral semaglutide in adults with type 2 diabetes in routine clinical practice. We report baseline characteristics of participants enrolled...
7.
Jain A, Reichert S, Amadid H, Braae U, Bradley R, Kim J, et al.
Diabetes Obes Metab
. 2024 Mar;
26(5):1799-1807.
PMID: 38468125
Aim: PIONEER REAL Canada examined real-world clinical outcomes associated with the use of once-daily oral semaglutide in adults with type 2 diabetes. Materials And Methods: This was a 34- to...
8.
Kick A, MRabet-Bensalah K, Acquistapace F, Amadid H, Ambuhl R, Braae U, et al.
Diabetes Ther
. 2024 Jan;
15(3):623-637.
PMID: 38240875
Introduction: Real-world data provide insight into how medications perform in clinical practice. The PIONEER REAL Switzerland study aimed to understand clinical outcomes with oral semaglutide in adults with type 2...
9.
Mizrak H, Hansen T, Rossing P, Curovic V, Vistisen D, Amadid H, et al.
Diabetes Care
. 2023 Aug;
46(11):1997-2003.
PMID: 37647323
Objective: It is not known if incidence rates for diabetic distal symmetric polyneuropathy (DSPN) are decreasing, as they are for other diabetic complications. Here, we investigated incidence rates of DSPN...
10.
Kosjerina V, Carstensen B, Amadid H, Vistisen D
Diabetologia
. 2023 Jul;
66(10):1908-1913.
PMID: 37505281
Aims/hypothesis: The aim of this study was to compare the performance of the second-generation basal insulins, insulin degludec 100 U/ml (Deg-100) and insulin glargine 300 U/ml (Gla-300), in terms of...